Investor Presentation First Nine Months of 2023
60
Investor presentation
First nine months of 2023
Patient access to anti-obesity medications is improving in both
the US and IO
The ~50 million people having access to WegovyⓇ demonstrates the
recognition of Obesity as a chronic disease
~110m
Obesity prevalence in US adults¹
~60m
Commercial Channel
>80% formulary access
• ~50% of employers opt-in
~38m
People with
commercial coverage
~12m
Medicaid²
Restricted reimbursement for SaxendaⓇ is progressing
EXAMPLES
BMI ≥ 30
with two or more co-morbidities
米
BMI ≥ 35
With pre-diabetes and risk of CV
(+)
~60% coverage by private insurance, 20% of
which includes restricted/unrestricted coverage
BMI ≥ 35
Or BMI ≥ 28 and one obesity related comorbidity
1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention, https://www.cdc.gov/obesity/data/adult.html; US Census Bureau. QuickFacts: United States. https://www.census.gov/quickfacts/fact/table/US#viewtop. Accessed Mar, 2021.;
2 Also includes DoD and government employees
Note: Obesity is defined as BMI > 30
Novo NordiskⓇView entire presentation